- Home
- ONCO vs SLRX Comparison
ONCO vs SLRX Comparison
Compare ONCO & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- SLRX
- Stock Information
- Founded
- ONCO 2018
- SLRX N/A
- Country
- ONCO United States
- SLRX United States
- Employees
- ONCO N/A
- SLRX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- SLRX Health Care
- Exchange
- ONCO Nasdaq
- SLRX Nasdaq
- Market Cap
- ONCO 4.3M
- SLRX 3.6M
- IPO Year
- ONCO 2022
- SLRX N/A
- Fundamental
- Price
- ONCO $2.21
- SLRX $0.91
- Analyst Decision
- ONCO
- SLRX
- Analyst Count
- ONCO 0
- SLRX 0
- Target Price
- ONCO N/A
- SLRX N/A
- AVG Volume (30 Days)
- ONCO 28.9K
- SLRX 5.0M
- Earning Date
- ONCO 11-13-2025
- SLRX 11-14-2025
- Dividend Yield
- ONCO N/A
- SLRX N/A
- EPS Growth
- ONCO N/A
- SLRX N/A
- EPS
- ONCO N/A
- SLRX N/A
- Revenue
- ONCO $1,223,751.00
- SLRX N/A
- Revenue This Year
- ONCO N/A
- SLRX N/A
- Revenue Next Year
- ONCO N/A
- SLRX N/A
- P/E Ratio
- ONCO N/A
- SLRX N/A
- Revenue Growth
- ONCO N/A
- SLRX N/A
- 52 Week Low
- ONCO $2.10
- SLRX $0.71
- 52 Week High
- ONCO $179.35
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- ONCO 33.70
- SLRX 24.73
- Support Level
- ONCO $2.17
- SLRX $0.71
- Resistance Level
- ONCO $2.53
- SLRX $1.29
- Average True Range (ATR)
- ONCO 0.20
- SLRX 0.33
- MACD
- ONCO -0.05
- SLRX -0.08
- Stochastic Oscillator
- ONCO 16.01
- SLRX 7.73
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.